TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Wedbush Securities
US financial services and investment firm
Nothing else this week.
Related events
- TD Cowen upgraded Cabaletta Bio shares to strong-buy, while Jefferies reissued a buy rating, and MarketBeat provided consensus data.
- TD Cowen, Stephens, Citigroup, and MarketBeat provided new analyst ratings and coverage for Covenant Logistics Group, Inc.
- Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen is managing a share offering for PMV Pharma, which has been filed with the SEC and utilizes Broadridge Financial Solutions for mailing the prospectus.